On May 14, 2026, Biogen announced the completion of its acquisition of Apellis Pharmaceuticals, following a successful tender offer where 82.4% of Apellis shares were tendered at $41.00 each, with up to $4.00 in contingent payments based on future sales milestones for their products, potentially totaling approximately $5.3 billion for the transaction.